A phase II study of cetuximab (Erbitux) with cisplatin and capecitabine (Xeloda) as 1st line treatment in the advanced gastric cancer.
Phase of Trial: Phase II
Latest Information Update: 20 May 2015
At a glance
- Drugs Cetuximab (Primary) ; Capecitabine; Cisplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms EXTRA
- 10 Jun 2017 Biomarkers information updated
- 18 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 10 Nov 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.